Honokiol acts as an AMPK complex agonist therapeutic in non-alcoholic fatty liver disease and metabolic syndrome

Honokiol acts as an AMPK complex agonist therapeutic in non-alcoholic fatty liver disease and metabolic syndrome

Abstract Background Non-alcoholic fatty liver (NAFLD) and its related metabolic syndrome have become major threats to human health, but there is still a need for effective and safe drugs to treat these conditions. Here we aimed to identify potential drug candidates for NAFLD and the underlying molec...

Full description

Bibliographic Details
Main Authors: Ruifeng Tian, Jinjie Yang, Xiaoming Wang, Shuaiyang Liu, Ruixiang Dong, Zhenya Wang, Zifeng Yang, Yingping Zhang, Zhiwei Cai, Hailong Yang, Yufeng Hu, Zhi-Gang She, Hongliang Li, Junjie Zhou, Xiao-Jing Zhang
Format: Article
Language:English
Published: BMC 2023-03-01
Series:Chinese Medicine
Subjects:
Honokiol
AMPKγ1
Non-alcoholic fatty liver disease
Obesity
Online Access:https://doi.org/10.1186/s13020-023-00729-5

Internet

https://doi.org/10.1186/s13020-023-00729-5

Similar Items